Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 14;18(2):27-35.
doi: 10.14797/mdcvj.1070. eCollection 2022.

Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication

Affiliations
Review

Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication

Kelty R Baker. Methodist Debakey Cardiovasc J. .

Abstract

Amyloidosis is a disorder of protein misfolding and metabolism in which insoluble fibrils are deposited in various tissues, causing organ dysfunction and eventually death. Out of the 60-plus heterogeneous amyloidogenic proteins that have been identified, approximately 30 are associated with human disease. The unifying feature of these proteins is their tendency to form beta-pleated sheets aligned in an antiparallel fashion. These sheets then form rigid, nonbranching fibrils that resist proteolysis, causing mechanical disruption and local oxidative stress in affected organs such as the heart, liver, kidneys, nervous system, and gastrointestinal tract. Here we review the epidemiology of light chain amyloidosis, the staging, and the concomitant prognostication that is critical in determining the appropriate treatment.

Keywords: Mayo Clinic staging system; cardiac amyloidosis; light chain amyloidosis; prognosis.

PubMed Disclaimer

Conflict of interest statement

The author has no competing interests to declare.

References

    1. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid. 2010. Sep;17(3-4):101-4. doi: 10.3109/13506129.2010.526812 - DOI - PubMed
    1. Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyhoid. 2020. Dec;27(4):217-222. doi: 10.1080/13506129.2020.1835263 - DOI - PubMed
    1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003. Aug 7;349(6):583-96. doi: 10.1056/NEJMra023144 - DOI - PubMed
    1. Comenzo RL. How I treat amyloidosis. Blood. 2009. Oct 8;114(15):3147-57. doi: 10.1182/blood-2009-04-202879 - DOI - PubMed
    1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997. Sep 25;337(13):898-909. doi: 10.1056/NEJM199709253371306 - DOI - PubMed

MeSH terms